Engineering the variable region of therapeutic IgG antibodies.
about
Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studiesRecent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal AntibodiesIdentification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activityOxidation in the complementarity-determining regions differentially influences the properties of therapeutic antibodiesThermodynamics of antibody-antigen interaction revealed by mutation analysis of antibody variable regions.CHO cell production and sequence improvement in the 13C6FR1 anti-Ebola antibody.Structural analysis of B-cell epitopes in antibody:protein complexesFc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.Anti-cadherin-17 antibody modulates beta-catenin signaling and tumorigenicity of hepatocellular carcinoma.Characterization and screening of IgG binding to the neonatal Fc receptor.Development trends for generation of single-chain antibody fragments.Antibody engineering for increased potency, breadth and half-life.Bridging the gap: facilities and technologies for development of early stage therapeutic mAb candidatesEliminating antibody polyreactivity through addition of N-linked glycosylation.Affinity Maturation of Monoclonal Antibody 1E11 by Targeted Randomization in CDR3 Regions Optimizes Therapeutic Antibody Targeting of HER2-Positive Gastric CancerStability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approachAntibody Derived Peptides for Detection of Ebola Virus Glycoprotein.Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgGAberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeysUsing antibodies to target cancer therapeutics.Molecular engineering of antibodies for therapeutic and diagnostic purposes.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Tau Immunotherapy.Antibodies as stratagems against cancer.Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation.Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms.The emerging role of biosensor-based epitope binning and mapping in antibody-based drug discovery.Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care?Role of the mobility of antigen binding site in high affinity antibody elucidated by surface plasmon resonance.Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques.Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody.Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.Aggregates, crystals, gels, and amyloids: intracellular and extracellular phenotypes at the crossroads of immunoglobulin physicochemical property and cell physiology.Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity.Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts.Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.Thermodynamic stability and flexibility characteristics of antibody fragment complexes.
P2860
Q26781698-AFA3AC2C-9D77-493F-A121-7A11FCCC2986Q28068946-D89B587B-E642-474A-AB86-03568B8A5EB5Q28487387-096B55F2-919B-49B1-95C5-CBA6A539EF0CQ28821982-339E00BA-4E19-4A61-A7C9-39FBCB31211BQ30374518-A5DC1A83-0B3E-4137-AC3F-D3ABD5BCCA80Q30383481-58604994-F028-41F9-8200-D6CAFD6AB543Q30525358-2C90574D-5861-4B82-82D1-96D14588A6E9Q34550963-3C2C17F5-BF5A-47C8-84F3-D5D8968BEE2BQ34988368-C69FF202-A889-4FB0-94D7-913AEA1DBC98Q35163945-EF1B164B-66B1-46E8-A539-CF8660621859Q35216785-034EE24E-D20F-4720-9BA6-E69203A38510Q35575206-8FC54A2B-0385-407E-B604-C3205C69B814Q35578028-D458D2DB-0288-4ECB-A272-8C75CA0B35C2Q35684786-99481345-5B8E-4521-82F6-D09B95F358EAQ35726067-72C2AD2F-7556-4611-B2A2-447880A2742EQ35764163-26CFBE27-2365-4572-ACD9-02ED8E47F273Q35816320-6C6A37BA-DDA6-40E5-974D-4BBD3B93D462Q35857869-3EEC5377-7E74-483B-B8A4-FFEFCBFCCC9BQ36211427-06A61BC2-289F-4C7C-A01F-4487896FDB78Q36759899-4BF33843-15B0-464A-8ABD-7C9B81741337Q37141605-637D5258-B320-4D84-A791-73DC188123F7Q38014920-4D183878-7876-40D0-9865-9A9A27C13E60Q38017581-6E7DF40C-B030-4863-921E-6DF73E9B1316Q38072598-5DAAC450-BB8D-4E5D-B2C3-83C839DCF3BFQ38628672-51A316A2-8DE1-4294-80B4-9ABC30604452Q38688747-F791533A-B7A4-439E-8127-447BBB9F11A6Q38728589-A54468AC-7688-4102-BEBF-AFF921FE1CCCQ38821056-8F38DC62-85FF-47C3-87FD-78204784BFFAQ38947826-FCA61146-D88F-4FED-BADC-5DA72FEF99DBQ39347886-9DB25D6B-572B-43A0-A34B-24511BE40BDBQ39505747-753E0676-509B-4842-9A6F-C606C74C66FEQ39711072-D4F001C4-6AE4-4B5D-ACE1-E7B802B1731EQ40545249-51F5FF1D-2784-4AEB-9929-8A6E29556035Q41104888-034021FA-C569-4C0A-8F3A-F3D99418F099Q41459506-7172342A-7523-44F1-8C42-EDCDBB0F5A30Q41831737-D1A15D30-965D-4E44-8053-A884C2A78C45Q42076342-974ABFEB-A12F-4DB1-B848-D8C16A0487B3Q42105327-6BB96A16-B2A4-4EAE-8BAF-D03ED7ED2C9CQ42107564-1C874CF8-2FDA-4724-B78F-CE4081B4BAB2Q42204547-2DA026CE-0753-4581-B57C-A56E8751E02D
P2860
Engineering the variable region of therapeutic IgG antibodies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Engineering the variable region of therapeutic IgG antibodies.
@en
Engineering the variable region of therapeutic IgG antibodies.
@nl
type
label
Engineering the variable region of therapeutic IgG antibodies.
@en
Engineering the variable region of therapeutic IgG antibodies.
@nl
prefLabel
Engineering the variable region of therapeutic IgG antibodies.
@en
Engineering the variable region of therapeutic IgG antibodies.
@nl
P2093
P2860
P356
P1476
Engineering the variable region of therapeutic IgG antibodies
@en
P2093
Hiroyuki Tsunoda
Kunihiro Hattori
Shinya Ishii
Taichi Kuramochi
Tomoyuki Igawa
P2860
P304
P356
10.4161/MABS.3.3.15234
P577
2011-05-01T00:00:00Z